-
Artelo Biosciences Analyst See It As An Emerging Biotech
Tuesday, July 8, 2025 - 3:06pm | 524Read More...D. Boral Capital upgraded Artelo Biosciences, Inc. (NASDAQ:ARTL) on Tuesday. The analyst upgraded from Hold to Buy and introduced a price forecast of $20. Analyst Jason Kolbert wrote, “We continue to view Artelo as an emerging biotechnology company focused on Cachexia and chemotherapy-induced...
-
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
Friday, September 10, 2021 - 10:21am | 495Read More...Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced earlier this week an agreement with Dr. Reddy's Laboratories Ltd (NYSE: RDY) to acquire its exclusive license of E7777, a late-stage oncology immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare form of non-Hodgkin...
-
Sorrento Therapeutics Has $4B Coronavirus Opportunity, Analyst Says
Tuesday, May 26, 2020 - 1:01pm | 352Read More...Sorrento Therapeutics Inc's (NASDAQ: SRNE) coronavirus program has been met with equal optimism and skepticism, which has led to wild swings in its stock price. The Sorrento Analyst Dawson James Securities analyst Jason Kolbert initiated coverage of Sorrento with a Buy rating and a $24...
-
OncoSec Shares Spike 17% After New Data Defended
Thursday, October 19, 2017 - 2:38pm | 824Read More...OncoSec Medical Inc (NASDAQ: ONCS) shares spiked about 20 percent intraday Thursday amid the release of positive mid-stage trial data for its investigational therapy ImmuoPulse IL-12 as a monotherapy and in combination with Pembrolizumab (Keytruda) for treating predicted anti-PD-1 non-responder...
-
What A Week For MannKind
Friday, October 6, 2017 - 1:21pm | 430Read More...MannKind Corporation (NASDAQ: MNKD) investors haven’t had much to cheer about lately, with the stock down more than 80 percent in the past three years. However, this week provided investors with a bit of optimism and traders with a huge opportunity for profits. What Happened? MannKind...
-
8 Ways To Play The AI Boom
Tuesday, September 26, 2017 - 9:24am | 983Read More...Investors hungry for pure-play artificial intelligence companies have sent share prices of a handful of smaller tech companies soaring in recent weeks. Here’s a look at eight stocks with an emphasis on AI that may still be mostly under-the-radar. 1. Veritone Benzinga first reported about...
-
Maxim Still Calling For 900% Upside At StemCells After Latest Phase II Data
Tuesday, April 19, 2016 - 11:41am | 245Read More...Dr. Stephen Huhn, CMO of StemCells Inc (NASDAQ: STEM) provided additional details regarding the ongoing Phase II Pathway Study in chronic cervical spinal cord injuries at the annual meeting of the American Spinal Injury Association on April 15. Maxim’s Jason Kolbert maintained a Buy...
-
Agenus Shares Spike Higher Following Mid-Day Upgrade To Buy From Maxim
Saturday, March 12, 2016 - 1:04pm | 408Read More...Shares of Agenus Inc (NASDAQ: AGEN) were trading up more than 9 percent on Friday afternoon, after Maxim Group upgraded its rating on the stock from Hold to Buy, while establishing a price target of $7.00. Analysts Jason McCarthy and Jason Kolbert highlighted a few elements behind their...
-
Wall Street's Best Think Gilead Will Continue To Outperform The Market
Monday, July 27, 2015 - 4:12pm | 451Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are down about 1.8 percent on Monday trading, ahead of the announcement of the company’s second quarter financial results, scheduled for after the market closes on Tuesday. According to Estimize, experts are projecting earnings of $2.64 per...
-
Gilead Still A 'Buy' After Harvoni Approval In Japan, Maxim Proclaims
Monday, July 6, 2015 - 10:04am | 238Read More...In a report published Monday, Maxim analyst Jason Kolbert maintained a Buy rating and $127 price target on Gilead Sciences, Inc. (NASDAQ: GILD), while mentioning that Harvoni had received approval in Japan. A majority of the population in Japan is genotype 1, a group for which Harvoni has...
-
Maxim Analyst Issues Update On Tekmira's Ebola Research Development
Monday, April 13, 2015 - 9:58am | 290Read More...In a report published Monday, Maxim Group analyst Jason Kolbert commented on Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)'s ongoing research into the Ebola virus. Tekmira is part of an international consortium known as the International Severe Acute Respiratory and Emerging Infection Consortium (...
-
What Maxim Thinks Of Cytori After Its Huge Week
Wednesday, April 8, 2015 - 12:53pm | 188Read More...In a report published Wednesday, Maxim Group analyst Jason Kolbert discussed Cytori Therapeutics Inc (NASDAQ: CYTX)'s announcement earlier this week that the European Medicines Agency Committee for Orphan Medicinal Products has designed Cytori's ECC S-50 cellular therapeutic as an orphan...
-
Is Gilead's Latest Japan Win Good News For Shareholders?
Tuesday, March 31, 2015 - 12:38pm | 554Read More...Gilead Sciences, Inc. (NASDAQ: GILD) announced on March 26 that Japan's Ministry of Health, Labour, and Welfare approved Sovaldi as a hepatitis C treatment. The approval comes a year and a half after the biotech company filed the New Drug Application, making Sovaldi the first Gilead drug...
-
Vertex Treatment May Have High Risk of Failure, Analyst Suggests
Tuesday, March 24, 2015 - 3:13pm | 203Read More...Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) recent results from a prospective cystic fibrosis treatment suggests the product has a high risk of failure, an analyst said Tuesday. Maxim Group's Jason Kolbert maintained a Hold rating on Vertex with a $121 target. Vertex is off 5 percent since...
-
Maxim: Our Vertex Pharma Thesis Is Unchanged
Friday, March 20, 2015 - 11:29am | 291Read More...In a report published Friday, Maxim Group analyst Jason Kolbert said that his thesis on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) remains unchanged for the following reasons: Kalydeco (ivafcaftor) has been approved for children with one of ten gating/conductance mutations, adding an...
